Drug
Cladribine Low Dose
Cladribine Low Dose: highest development phase Phase 3, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cladribine Low Dose NCT06463587 | Phase 3 | Generalized Myasthenia Gravis |
Latest
No recent events.
Follow Cladribine Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.